Gottenberg JE, et al. - In this trial, the effectiveness and safety of epratuzumab, a CD22-targeted humanized monoclonal IgG1 antibody, were evaluated by the researchers in individuals presenting with systemic lupus erythematosus (SLE). Improvements were yielded in the SLE disease activity among patients with SLE and associated Sjögren's syndrome (aSjS) treated with epratuzumab. This, in turn, correlated with bioactivity, such as decreases in B cells and IgM.